- Home
- ACAD vs SMTC Comparison
ACAD vs SMTC Comparison
Compare ACAD & SMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- SMTC
- Stock Information
- Founded
- ACAD 1993
- SMTC 1960
- Country
- ACAD United States
- SMTC United States
- Employees
- ACAD N/A
- SMTC N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- SMTC Semiconductors
- Sector
- ACAD Health Care
- SMTC Technology
- Exchange
- ACAD Nasdaq
- SMTC Nasdaq
- Market Cap
- ACAD 4.0B
- SMTC 4.3B
- IPO Year
- ACAD 2004
- SMTC N/A
- Fundamental
- Price
- ACAD $25.99
- SMTC $58.09
- Analyst Decision
- ACAD Buy
- SMTC Strong Buy
- Analyst Count
- ACAD 20
- SMTC 13
- Target Price
- ACAD $28.63
- SMTC $59.92
- AVG Volume (30 Days)
- ACAD 2.0M
- SMTC 2.1M
- Earning Date
- ACAD 08-06-2025
- SMTC 08-25-2025
- Dividend Yield
- ACAD N/A
- SMTC N/A
- EPS Growth
- ACAD 615.00
- SMTC N/A
- EPS
- ACAD 1.33
- SMTC 0.29
- Revenue
- ACAD $1,018,885,000.00
- SMTC $996,476,000.00
- Revenue This Year
- ACAD $14.01
- SMTC $15.81
- Revenue Next Year
- ACAD $11.72
- SMTC $9.69
- P/E Ratio
- ACAD $19.61
- SMTC $201.52
- Revenue Growth
- ACAD 14.41
- SMTC 22.22
- 52 Week Low
- ACAD $13.40
- SMTC $24.05
- 52 Week High
- ACAD $26.65
- SMTC $79.52
- Technical
- Relative Strength Index (RSI)
- ACAD 62.55
- SMTC 63.38
- Support Level
- ACAD $25.14
- SMTC $46.02
- Resistance Level
- ACAD $26.65
- SMTC $61.40
- Average True Range (ATR)
- ACAD 0.67
- SMTC 2.74
- MACD
- ACAD 0.04
- SMTC 0.84
- Stochastic Oscillator
- ACAD 70.27
- SMTC 78.48
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About SMTC Semtech Corporation
Semtech Corp is engaged in designing, developing, manufacturing and marketing analog and mixed-signal semiconductors, algorithms and wireless semiconductors, connectivity modules, gateways, routers and connected services for IoT. The company operates in four reportable segments: Signal Integrity, Analog Mixed Signal and Wireless, IoT Systems and IoT Connected Services. The majority of the company's revenue is earned through Analog Mixed Signal and Wireless segment. Geographically majority of the company's revenue is earned from Asia Pacific region, company also operates in North America and Europe.